Agios Pharmaceuticals (AGIO) Depreciation and Depletion (2012 - 2020)

Agios Pharmaceuticals' Depreciation and Depletion history runs 9 years deep, the most recent figure standing at $2.4 million for Q2 2020.

• Quarterly Depreciation and Depletion rose 19.39% year-over-year to $2.4 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $8.9 million (up 13.96% YoY) and the FY2025 annual result came in at $5.2 million, down 8.77% from the prior year.
• Depreciation and Depletion was $2.4 million for Q2 2020 at Agios Pharmaceuticals, down from $2.5 million in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $2.5 million in Q1 2020 and bottomed at $1.2 million in Q1 2016.
• A 5-year average of $1.8 million and a median of $1.7 million in 2018 frame the typical range for Depreciation and Depletion.
• Annual changes were most pronounced in 2016 — Depreciation and Depletion surged 236.76% — and 2017, when it retreated 5.37%.
• Agios Pharmaceuticals' Depreciation and Depletion stood at $1.7 million in 2016, then retreated by 5.37% to $1.6 million in 2017, then climbed by 19.54% to $1.9 million in 2018, then slipped by 3.25% to $1.9 million in 2019, then advanced by 29.64% to $2.4 million in 2020.
• Business Quant data shows AGIO's Depreciation and Depletion at $2.4 million in Q2 2020, $2.5 million in Q1 2020, and $1.9 million in Q4 2019.